Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection. research hub

BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

This study looks at a new treatment called Bevacizumab for adults who still feel breathless long after having COVID-19. Researchers want to see if it can help improve their breathing over three months and if it's safe to use.